MediciNova Reaches 100-Patient Milestone in Expanded Access Program for ALS Treatment

MediciNova (NASDAQ: MNOV) announced that 100 patients with amyotrophic lateral sclerosis (ALS) have now been enrolled in its SEANOBI Expanded Access Program (EAP) evaluating MN-166 (ibudilast), marking a meaningful participation milestone for the company’s lead neuroinflammation-focused asset.

The Expanded Access Program allows eligible ALS patients to receive ibudilast outside of traditional clinical trials, reflecting growing physician and patient interest in the therapy amid limited treatment options for this fatal neurodegenerative disease.

Why This Matters for Investors

Reaching 100 enrolled patients signals real-world demand for ibudilast and sustained engagement from the ALS community. While expanded access programs are not designed to demonstrate efficacy, participation levels can offer insight into clinician confidence, patient awareness, and the perceived therapeutic relevance of an investigational drug.

For investors, this milestone reinforces momentum around MN-166 and supports MediciNova’s broader strategy to advance the compound across neurodegenerative indications where inflammation and glial activation are believed to play a role in disease progression.

Supporting the ALS Development Strategy

Ibudilast has been studied across multiple central nervous system disorders, and the SEANOBI program complements MediciNova’s ongoing clinical and regulatory efforts in ALS. Expanded access programs can also help increase familiarity among physicians and treatment centers, potentially smoothing future trial enrollment and supporting long-term commercialization discussions.

ALS remains an area of high unmet medical need, and therapies that can slow progression — even modestly — are closely followed by both patients and investors.

Broader Context

Expanded access programs operate under FDA oversight and are intended for patients who cannot participate in clinical trials and lack satisfactory treatment alternatives. While data generated from EAPs are not registrational, they can contribute to a broader understanding of safety and use patterns in real-world settings.

For small-cap biotech companies, sustained EAP participation can also serve as a sentiment indicator, highlighting continued relevance of a program while formal clinical development progresses.

Bottom Line

MediciNova’s achievement of 100 enrolled ALS patients in its SEANOBI Expanded Access Program represents a constructive engagement milestone for MN-166 and underscores continued interest in the therapy among clinicians and patients. For MNOV investors, the update supports the narrative that ibudilast remains a central value driver as the company advances its ALS strategy and works toward future clinical and regulatory catalysts.